Insulin-Like Growth Factor-1 and Central Neurodegenerative Diseases

Endocrinology and Metabolism Clinics of North America

Volumn 41, Issue 2, 2012, Pages 395-408

  Torres Aleman, Ignacio ^a,b  

^a INSTITUTO CAJAL   (Spain)

^b NONE

Author keywords

Aging; Neurodegeneration; Neurotrophic input

Indexed keywords

PROTEIN KINASE C INHIBITOR; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

AGING; ALZHEIMER DISEASE; AUTOPHAGY; BRAIN ISCHEMIA; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; ENZYME REGULATION; EXCITOTOXICITY; HUMAN; INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; TREATMENT RESPONSE; UNFOLDED PROTEIN RESPONSE;

AGING; ANIMALS; AUTOPHAGY; CENTRAL NERVOUS SYSTEM DISEASES; ENDOPLASMIC RETICULUM STRESS; HUMANS; INFLAMMATION; INSULIN-LIKE GROWTH FACTOR I; MICE; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; RATS; RECEPTOR, IGF TYPE 1; UNFOLDED PROTEIN RESPONSE;

EID: 84861980735     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2012.04.016     Document Type: Review

References (100)

1. Allan S.M., Rothwell N.J. Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001, 2(10):734-744.
2. Beattie E.C., Stellwagen D., Morishita W., et al. Control of synaptic strength by glial TNFalpha. Science 2002, 295(5563):2282-2285.
3. Freude S., Schilbach K., Schubert M. The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. Curr Alzheimer Res 2009, 6(3):213-223.
4. Torres-Aleman I. Toward a comprehensive neurobiology of IGF-I. Dev Neurobiol 2010, 70(5):384-396.
5. Nishijima T., Piriz J., Duflot S., et al. Neuronal activity drives localized blood-brain-barrier transport of serum insulin-like growth factor-I into the CNS. Neuron 2010, 67(5):834-846.
6. Christensen K., Doblhammer G., Rau R., et al. Ageing populations: the challenges ahead. Lancet 2009, 374(9696):1196-1208.
7. Douglas P.M., Dillin A. Protein homeostasis and aging in neurodegeneration. J Cell Biol 2010, 190(5):719-729.
8. Kleemann G.A., Murphy C.T. The endocrine regulation of aging in Caenorhabditis elegans. Mol Cell Endocrinol 2009, 299(1):51-57.
9. Kenyon C.J. The genetics of ageing. Nature 2010, 464(7288):504-512.
10. Bartke A. The somatotropic axis and aging: mechanisms and persistent questions about practical implications. Exp Gerontol 2009, 44(6-7):372-374.
11. Liu J.P., Baker J., Perkins A.S., et al. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993, 75(1):59-72.
12. Kojima T., Kamei H., Aizu T., et al. Association analysis between longevity in the Japanese population and polymorphic variants of genes involved in insulin and insulin-like growth factor 1 signaling pathways. Exp Gerontol 2011, 39(11-12):1595-1598.
13. Cohen E., Paulsson J.F., Blinder P., et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 2009, 139(6):1157-1169.
14. Gusella J.F., MacDonald M.E. Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci 2000, 1(2):109-115.
15. Sastre M., Walter J., Gentleman S.M. Interactions between APP secretases and inflammatory mediators. J Neuroinflammation 2008, 5:25.
16. Trejo J.L., Carro E., Garcia-Galloway E., et al. Role of insulin-like growth factor I signaling in neurodegenerative diseases. J Mol Med 2004, 82(3):156-162.
17. Mrak R.E., Griffin W.S. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 2005, 26(3):349-354.
18. Glass C.K., Saijo K., Winner B., et al. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140(6):918-934.
19. Fernandez A.M., Jimenez S., Mecha M., et al. Regulation of the phosphatase calcineurin by insulin-like growth factor I unveils a key role of astrocytes in Alzheimer's pathology. Mol Psychiatry 2011, 10.1038/mp.2011.128.
20. Imbimbo B.P. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease. Expert Opin Investig Drugs 2009, 18(8):1147-1168.
21. Grimble R.F. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 2002, 5(5):551-559.
22. Venters H.D., Tang Q., Liu Q., et al. A new mechanism of neurodegeneration: a proinflammatory cytokine inhibits receptor signaling by a survival peptide. Proc Natl Acad Sci U S A 1999, 96(17):9879-9884.
23. Arundine M., Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 2003, 34(4-5):325-337.
24. Garcia-Galloway E., Arango C., Pons S., et al. Glutamate excitotoxicity attenuates insulin-like growth factor-i prosurvival signaling. Mol Cell Neurosci 2003, 24(4):1027-1037.
25. Zheng W.H., Quirion R. Glutamate acting on NMDA receptors attenuates IGF-1 receptor tyrosine phosphorylation and its survival signaling properties in rat hippocampal neurons. J Biol Chem 2009, 284(2):855-861.
26. Guan J., Bennet L., Gluckman P.D., et al. Insulin-like growth factor-1 and post-ischemic brain injury. Prog Neurobiol 2003, 70(6):443-462.
27. Goldstein B.J., Mahadev K., Wu X. Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes 2005, 54(2):311-321.
28. Droge W. Oxidative stress and aging. Adv Exp Med Biol 2003, 543:191-200.
29. Yang W., Hekimi S. A mitochondrial superoxide signal triggers increased longevity in caenorhabditis elegans. PLoS Biol 2010, 8(12):e1000556.
30. Houstis N., Rosen E.D., Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440(7086):944-948.
31. Davila D., Torres-Aleman I. Neuronal death by oxidative stress involves activation of FOXO3 through a two-arm pathway that activates stress kinases and attenuates insulin-like growth factor I signaling. Mol Biol Cell 2008, 19(5):2014-2025.
32. Kim B., Sullivan K.A., Backus C., et al. Cortical neurons develop insulin resistance and blunted Akt signaling: a potential mechanism contributing to enhanced ischemic injury in diabetes. Antioxid Redox Signal 2011, 14(10):1829-1839.
33. Hara T., Nakamura K., Matsui M., et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441(7095):885-889.
34. Komatsu M., Waguri S., Chiba T., et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441(7095):880-884.
35. Lee J.A. Autophagy in neurodegeneration: two sides of the same coin. BMB Rep 2009, 42(6):324-330.
36. Bains M., Zaegel V., Mize-Berge J., et al. IGF-I stimulates Rab7-RILP interaction during neuronal autophagy. Neurosci Lett 2011, 488(2):112-117.
37. Ravikumar B., Vacher C., Berger Z., et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004, 36(6):585-595.
38. Yamamoto A., Cremona M.L., Rothman J.E. Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J Cell Biol 2006, 172(5):719-731.
39. Feng Z., Levine A.J. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 2010, 20(7):427-434.
40. Haruta T., Uno T., Kawahara J., et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 2000, 14(6):783-794.
41. Rutkowski D.T., Arnold S.M., Miller C.N., et al. Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biol 2006, 4(11):e374.
42. Engin F., Hotamisligil G.S. Restoring endoplasmic reticulum function by chemical chaperones: an emerging therapeutic approach for metabolic diseases. Diabetes Obes Metab 2010, 12(Suppl 2):108-115.
43. Shore G.C., Papa F.R., Oakes S.A. Signaling cell death from the endoplasmic reticulum stress response. Curr Opin Cell Biol 2011, 23(2):143-149.
44. Bouman L., Schlierf A., Lutz A.K., et al. Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. Cell Death Differ 2011, 18(5):769-782.
45. Matus S., Nassif M., Glimcher L.H., et al. XBP-1 deficiency in the nervous system reveals a homeostatic switch to activate autophagy. Autophagy 2009, 5(8):1226-1228.
46. Ozcan U., Cao Q., Yilmaz E., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306(5695):457-461.
47. Novosyadlyy R., Kurshan N., Lann D., et al. Insulin-like growth factor-I protects cells from ER stress-induced apoptosis via enhancement of the adaptive capacity of endoplasmic reticulum. Cell Death Differ 2008, 15(8):1304-1317.
48. Pfaffenbach K.T., Lee A.S. The critical role of GRP78 in physiologic and pathologic stress. Curr Opin Cell Biol 2011, 23(2):150-156.
49. Rubovitch V., Shahar A., Werner H., et al. Does IGF-1 administration after a mild traumatic brain injury in mice activate the adaptive arm of ER stress?. Neurochem Int 2011, 8(4):443-446.
50. Park S.W., Zhou Y., Lee J., et al. The regulatory subunits of PI3K, p85[alpha] and p85[beta], interact with XBP-1 and increase its nuclear translocation. Nat Med 2010, 16(4):429-437.
51. Hu M.C., Gong H.Y., Lin G.H., et al. XBP-1, a key regulator of unfolded protein response, activates transcription of IGF1 and Akt phosphorylation in zebrafish embryonic cell line. Biochem Biophys Res Commun 2007, 359(3):778-783.
52. Ishigaki S., Fonseca S.G., Oslowski C.M., et al. AATF mediates an antiapoptotic effect of the unfolded protein response through transcriptional regulation of AKT1. Cell Death Differ 2010, 17(5):774-786.
53. Endo H., Murata K., Mukai M., et al. Activation of insulin-like growth factor signaling induces apoptotic cell death under prolonged hypoxia by enhancing endoplasmic reticulum stress response. Cancer Res 2007, 67(17):8095-8103.
54. Puglielli L. Aging of the brain, neurotrophin signaling, and Alzheimer's disease: is IGF1-R the common culprit?. Neurobiol Aging 2008, 29(6):795-811.
55. Monnat R.J. From broken to old: DNA damage, IGF1 endocrine suppression and aging. DNA Repair 2007, 6(9):1386-1390.
56. Marino G., Ugalde A.P., Fernandez A.F., et al. Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function. Proc Natl Acad Sci U S A 2010, 107(37):16268-16273.
57. Endres M., Piriz J., Gertz K., et al. Serum insulin-like growth factor I and ischemic brain injury. Brain Res 2007, 1185:328-335.
58. Schwab S., Spranger M., Krempien S., et al. Plasma insulin-like growth factor I and IGF binding protein 3 levels in patients with acute cerebral ischemic injury. Stroke 1997, 28(9):1744-1748.
59. Moloney A.M., Griffin R.J., Timmons S., et al. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 2010, 31(2):224-243.
60. Salehi Z., Mashayekhi F., Naji M. Insulin like growth factor-1 and insulin like growth factor binding proteins in the cerebrospinal fluid and serum from patients with Alzheimer's disease. Biofactors 2008, 33(2):99-106.
61. Tham A., Nordberg A., Grissom F.E., et al. Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J Neural Transm Park Dis Dement Sect 1993, 5(3):165-176.
62. Vardy E.R., Rice P.J., Bowie P.C., et al. Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. J Alzheimers Dis 2007, 12(4):285-290.
63. Rivera E.J., Goldin A., Fulmer N., et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005, 8(3):247-268.
64. Watanabe T., Miyazaki A., Katagiri T., et al. Relationship between serum insulin-like growth factor-1 levels and Alzheimer's disease and vascular dementia. J Am Geriatr Soc 2005, 53(10):1748-1753.
65. Carro E., Trejo J.L., Gerber A., et al. Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol Aging 2006, 27(9):1250-1257.
66. Carro E., Trejo J.L., Gomez-Isla T., et al. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 2002, 8(12):1390-1397.
67. Lanz T.A., Salatto C.T., Semproni A.R., et al. Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models. Biochem Pharmacol 2008, 75(5):1093-1103.
68. Kenyon C. A conserved regulatory system for aging. Cell 2001, 105(2):165-168.
69. Redman L.M., Martin C.K., Williamson D.A., et al. Effect of caloric restriction in non-obese humans on physiological, psychological and behavioral outcomes. Physiol Behav 2008, 94(5):643-648.
70. Pehar M., O'Riordan K.J., Burns-Cusato M., et al. Altered longevity-assurance activity of p53: p44 in the mouse causes memory loss, neurodegeneration and premature death. Aging Cell 2010, 9(2):174-190.
71. Holzenberger M., Dupont J., Ducos B., et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 2003, 421(6919):182-187.
72. Freude S., Hettich M.M., Schumann C., et al. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J 2009, 23:3315.
73. Killick R., Scales G., Leroy K., et al. Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun 2009, 386(1):257-262.
74. Carro E., Trejo J.L., Spuch C., et al. Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease?. Neurobiol Aging 2006, 27(11):1618-1631.
75. Mawuenyega K.G., Sigurdson W., Ovod V., et al. Decreased clearance of CNS +|-amyloid in Alzheimer's disease. Science 2010, 330(6012):1774.
76. Adlerz L., Holback S., Multhaup G., et al. IGF-1-induced processing of the amyloid precursor protein family is mediated by different signaling pathways. J Biol Chem 2007, 282(14):10203-10209.
77. Shineman D.W., Dain A.S., Kim M.L., et al. Constitutively active Akt inhibits trafficking of amyloid precursor protein and amyloid precursor protein metabolites through feedback inhibition of phosphoinositide 3-kinase. Biochemistry 2009, 48(17):3787-3794.
78. McElroy B., Powell J.C., McCarthy J.V. The insulin-like growth factor 1 (IGF-1) receptor is a substrate for gamma-secretase-mediated intramembrane proteolysis. Biochem Biophys Res Commun 2007, 358(4):1136-1141.
79. Farris W., Mansourian S., Chang Y., et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 2003, 100(7):4162-4167.
80. Fishel M.A., Watson G.S., Montine T.J., et al. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol 2005, 62(10):1539-1544.
81. Selkoe D.J., Wolfe M.S. Presenilin: running with scissors in the membrane. Cell 2007, 131(2):215-221.
82. Nakajima M., Watanabe S., Okuyama S., et al. Restricted growth and insulin-like growth factor-1 deficiency in mice lacking presenilin-1 in the neural crest cell lineage. Int J Dev Neurosci 2009, 27(8):837-843.
83. Qin W., Jia J. Down-regulation of insulin-degrading enzyme by presenilin 1 V97L mutant potentially underlies increased levels of amyloid beta 42. Eur J Neurosci 2008, 27(9):2425-2432.
84. Lopez-Lopez C., Dietrich M.O., Metzger F., et al. Disturbed cross talk between insulin-like growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of Alzheimer's disease. J Neurosci 2007, 27(4):824-831.
85. Piriz J., Muller A., Trejo J.L., et al. IGF-I and the aging mammalian brain. Exp Gerontol 2011, 46(2-3):96-99.
86. Sehat B., Tofigh A., Lin Y., et al. SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal 2010, 3(108):ra10.
87. Boucher J., Macotela Y., Bezy O., et al. A kinase-independent role for unoccupied insulin and IGF-1 receptors in the control of apoptosis. Sci Signal 2010, 3(151):ra87.
88. De Felice F.G., Vieira M.N., Bomfim T.R., et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of A+| oligomers. Proc Natl Acad Sci U S A 2009, 106(6):1971-1976.
89. Ma Q.L., Yang F., Rosario E.R., et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 2009, 29(28):9078-9089.
90. Carro E., Torres-Aleman I. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 2004, 490(1-3):127-133.
91. Gasparini L., Xu H. Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci 2003, 26(8):404-406.
92. Busiguina S., Fernandez A.M., Barrios V., et al. Neurodegeneration is associated to changes in serum insulin-like growth factors. Neurobiol Dis 2000, 7(6 Pt B):657-665.
93. Gatchel J.R., Watase K., Thaller C., et al. The insulin-like growth factor pathway is altered in spinocerebellar ataxia type 1 and type 7. Proc Natl Acad Sci U S A 2008, 105(4):1291-1296.
94. Peretz S., Jensen R., Baserga R., et al. ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response. Proc Natl Acad Sci U S A 2001, 98(4):1676-1681.
95. Saute J.A., da Silva A.C., Muller A.P., et al. Serum insulin-like system alterations in patients with spinocerebellar ataxia type 3. Mov Disord 2011, 26(4):731-735.
96. Torres-Aleman I., Barrios V., Lledo A., et al. The insulin-like growth factor I system in cerebellar degeneration. Ann Neurol 1996, 39(3):335-342.
97. Acerini C.L., Dunger D.B. Insulin-like growth factor-I for the treatment of type 1 diabetes. Diabetes Obes Metab 2000, 2(6):335-343.
98. Arpa J., Sanz-Gallego I., Medina-Baez J., et al. Subcutaneous insulin-like growth factor-1 treatment in spinocerebellar ataxias: an open label clinical trial. Mov Disord 2011, 26(2):358-359.
99. Clemmons D.R., Moses A.C., Sommer A., et al. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res 2005, 15(4):265-274.
100. Jucker M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med 2010, 16(11):1210-1214.